Search the Newsreel

How Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story

Ionis Pharmaceuticals and AstraZeneca recently reported that their Phase 3 CARDIO-TTRansform trial of eplontersen in transthyretin amyloidosis cardiomyopathy did not meet its primary efficacy endpoint, prompting a shareholder investigation into the transparency of trial data and design. This setback removes a late-stage cardiovascular candidate …

AstraZeneca Secures EU Nod For Etcamah In Advanced Breast Cancer

(RTTNews) - AstraZeneca (AZN) on Thursday announced that the company's Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been approved in the European Union or EU for the treatment of adult patients for an advanced breast …

Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics

Wall Street analysts expect Astrazeneca (AZN) to post quarterly earnings of $2.50 per share in its upcoming report, which indicates a year-over-year increase of 14.7%. Revenues are expected to be $15.31 billion, up 5.9% from the year-ago quarter. The current level reflects a downward …

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Royalty Pharma plc NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront. Cliramitug is a Phase …

Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know

Astrazeneca (AZN) closed at $164.52 in the latest trading session, marking a -2.59% move from the prior day. This change lagged the S&P 500's 0.19% loss on the day. Elsewhere, the Dow lost 0.59%, while the tech-heavy Nasdaq lost 0.05%. The pharmaceutical's stock has …

Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …

What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …

Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. NeoGenomics (NEO) drew fresh attention after announcing PTEN IHC CDx, an FDA approved companion …

Leerink raises AstraZeneca stock price target to $220 on COPD drug data